Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study

[1]  B. Lambermont,et al.  Detection of decreased glomerular filtration rate in intensive care units: serum cystatin C versus serum creatinine , 2014, BMC Nephrology.

[2]  V. Briedis,et al.  Augmented renal clearance – an evolving risk factor to consider during the treatment with vancomycin , 2013, Journal of clinical pharmacy and therapeutics.

[3]  K. Bailey,et al.  Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease , 2013, Kidney international.

[4]  Y. Song,et al.  Serum Cystatin C Is a Major Predictor of Vancomycin Clearance in a Population Pharmacokinetic Analysis of Patients with Normal Serum Creatinine Concentrations , 2013, Journal of Korean medical science.

[5]  E. Schaeffner,et al.  Two Novel Equations to Estimate Kidney Function in Persons Aged 70 Years or Older , 2012, Annals of Internal Medicine.

[6]  A. Khwaja.  KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.

[7]  M. Joffe,et al.  Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  Harold I Feldman,et al.  Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.

[9]  E. Grace.  Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. , 2012, The Journal of antimicrobial chemotherapy.

[10]  R. Wunderink,et al.  Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  A. Padiglione,et al.  Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels , 2012, Internal medicine journal.

[12]  A. Okparavero,et al.  Cystatin C as a marker of glomerular filtration rate: prospects and limitations , 2011, Current opinion in nephrology and hypertension.

[13]  R. Kullar,et al.  Validation of the Effectiveness of a Vancomycin Nomogram in Achieving Target Trough Concentrations of 15–20 mg/L Suggested by the Vancomycin Consensus Guidelines , 2011, Pharmacotherapy.

[14]  Carsten Gnewuch,et al.  Clearance of vancomycin during continuous infusion in Intensive Care Unit patients: correlation with measured and estimated creatinine clearance and serum cystatin C. , 2010, International journal of antimicrobial agents.

[15]  R. Perkins,et al.  Acute kidney injury in the critically ill, morbidly obese patient: diagnostic and therapeutic challenges in a unique patient population. , 2010, Critical care clinics.

[16]  Michael Barras,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. , 2010, The Clinical biochemist. Reviews.

[17]  Tomoyoshi Inoue,et al.  Population Pharmacokinetic Analysis of Vancomycin Using Serum Cystatin C as a Marker of Renal Function , 2009, Antimicrobial Agents and Chemotherapy.

[18]  Kent Doi,et al.  Reduced production of creatinine limits its use as marker of kidney injury in sepsis. , 2009, Journal of the American Society of Nephrology : JASN.

[19]  K. Bailey,et al.  For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics. , 2009, Kidney international.

[20]  Christopher H Schmid,et al.  Factors other than glomerular filtration rate affect serum cystatin C levels. , 2009, Kidney international.

[21]  W. van Biesen,et al.  Acute renal problems in the critically ill cancer patient , 2008, Current opinion in critical care.

[22]  John W. Wilson,et al.  Mayo Clinic Antimicrobial Therapy : Quick Guide , 2008 .

[23]  V. Lindström,et al.  Standardization of Cystatin C: Development of primary and secondary reference preparations , 2008, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[24]  M. Murase,et al.  Hoek's formula, a cystatin C-based prediction formula for determining the glomerular filtration rate, is the most effective method for original adjusting the dosage of vancomycin. , 2007, International journal of clinical pharmacology and therapeutics.

[25]  Tomoyoshi Inoue,et al.  Estimation of the Initial Dose Setting of Vancomycin Therapy With Use of Cystatin C as a New Marker of Renal Function , 2007, Therapeutic drug monitoring.

[26]  Y. Kagawa,et al.  Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients. , 2007, Clinical biochemistry.

[27]  J. Hermida,et al.  Serum Cystatin C for the Prediction of Glomerular Filtration Rate With Regard to the Dose Adjustment of Amikacin, Gentamicin, Tobramycin, and Vancomycin , 2006, Therapeutic drug monitoring.

[28]  T. Larson,et al.  Glomerular filtration rate estimated by cystatin C among different clinical presentations. , 2006, Kidney international.

[29]  V. Teplan,et al.  Predicting the glomerular filtration rate from serum creatinine, serum cystatin C and the Cockcroft and Gault formula with regard to drug dosage adjustment. , 2004, International journal of clinical pharmacology and therapeutics.

[30]  D. Fish,et al.  Assessing renal function in cirrhotic patients: problems and pitfalls. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  D. Thompson,et al.  Historical Yearly Usage of Vancomycin , 1998, Antimicrobial Agents and Chemotherapy.

[32]  L. Melton,et al.  The threat to medical-records research. , 1997, The New England journal of medicine.

[33]  R. Wenzel,et al.  The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. , 1993, JAMA.

[34]  D. DuBois,et al.  A formula to estimate the approximate surface area if height and weight be known , 1989 .

[35]  D. Salazar,et al.  Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. , 1988, The American journal of medicine.

[36]  D. Cocchetto,et al.  Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance. , 1983, Therapeutic drug monitoring.

[37]  D J Greenblatt,et al.  Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. , 1981, Annals of internal medicine.

[38]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[39]  D. D. Bois,et al.  CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .

[40]  Brenda R. Hemmelgarn,et al.  Notice , 2012, Kidney International Supplements.

[41]  I. Njølstad,et al.  The role of cystatin C in improving GFR estimation in the general population. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[42]  Norbert Lameire,et al.  Notice , 2012, Kidney International Supplements.

[43]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  M. Rybak,et al.  The pharmacokinetic and pharmacodynamic properties of vancomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  D. Levine,et al.  Vancomycin: a history. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.